DAPT After PCI in High Bleeding Risk: Should Diabetes Influence Duration?
| Autor: | Marquis-Gravel G; Montreal Heart Institute, Université de Montréal, Montreal, Quebec, Canada. Electronic address: Guillaume.Marquis.Gravel@umontreal.ca., Costa F; Área Del Corazón, Hospital Universitario Virgen de la Victoria, Centro de Investigacion Biomedical en Red Enfermedades Cardiovasculares, Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina, Departamento de Medicina UMA, Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares, Malaga, Spain. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | JACC. Cardiovascular interventions [JACC Cardiovasc Interv] 2024 Nov 25; Vol. 17 (22), pp. 2678-2680. |
| DOI: | 10.1016/j.jcin.2024.09.027 |
| Abstrakt: | Competing Interests: Funding Support and Author Disclosures Dr Marquis-Gravel is a Junior 1 Clinical Research Scholar of the Fonds de Recherche du Québec–Santé; and has received consulting and/or speaker fees from Novartis, Novo Nordisk, JAMP Pharma, and HLS Therapeutics in the past 2 years. Dr Costa has reported that he has no relationships relevant to the contents of this paper to disclose. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|